Somatostatin receptors (sst1-5) are present in different types of tumors, where they inhibit key cellular processes such as proliferation and invasion. Although ssts are densely expressed in breast cancer, especially sst2, their role and therapeutic potential remain uncertain. Recently, we identified a new truncated sst5 variant, sst5TMD4, which is related to the abnormal response of certain pituitary tumors to treatment with somatostatin analogs. Here, we investigated the possible role of sst5TMD4 in breast cancer. This study revealed that sst5TMD4 is absent in normal mammary gland, but is abundant in a subset of poorly differentiated human breast tumors, where its expression correlated to that of sst2. Moreover, in the MCF-7 breast cancer model cell, sst5TMD4 expression increased malignancy features such as invasion and proliferation abilities (both in cell cultures and nude mice). This was likely mediated by sst5TMD4-induced increase in phosphorylated extracellular signal-regulated kinases 1 and 2 and p-Akt levels, and cyclin D3 and Arp2/3 complex expression, which also led to mesenchymal-like phenotype. Interestingly, sst5TMD4 interacts physically with sst2 and thereby alters its signaling, enabling disruption of sst2 inhibitory feedback and providing a plausible basis for our findings. These results suggest that sst5TMD4 could be involved in the pathophysiology of certain types of breast tumors.
Introduction
Breast cancer is the most frequent type of cancer in women (28%) and the second most frequent neoplasia overall (Ferlay et al., 2010; Jemal et al., 2010) . Although its incidence is stabilized, breast cancer is the second cause of death among neoplastic malignancies in women, with a mortality rate of B18% (Ferlay et al., 2010; Jemal et al., 2010) . Fortunately, efforts at identifying new, earlier diagnostic/prognostic factors, specific molecular signatures and novel therapeutic targets provide increasingly powerful tools to combat this pathology. In this scenario, it is disappointing that a likely valuable system, such as the one comprised by somatostatin (SST), its receptors (ssts) and synthetic analogs, has an unexpected marginal role and has received hitherto little attention.
The sst family comprises five G protein-coupled, seven-transmembrane domain receptors (sst1-5) widely distributed in normal and tumor tissues (Moller et al., 2003) . Additionally, we recently identified two new truncated sst5 variants, sst5TMD5 and sst5TMD4, generated by non-canonical splicing, which are overexpressed in pituitary tumors (Duran-Prado et al., 2009) , where they have a negative role, hindering the normal response of tumor cells to SST analogs (Dura´n-Prado et al., 2010) .
Earlier reports indicated that ssts are densely expressed in breast cancers compared with normal tissues. Specifically, 50-70% of breast tumors are positive for ssts (van Eijck et al., 1994) being sst2, overall, the most frequently and abundantly expressed in tumor cells (Orlando et al., 2004) . Indeed, sst2 is considered a good prognosis factor due to its association with low proliferative and invasive breast cancers (Orlando et al., 2004) . Moreover, sst2 expression loss in certain cancer cells results in the elimination of an autocrine inhibitory feedback loop, which leads to phenotypic and functional alterations (Benali et al., 2000; Leu et al., 2008) , including epithelial-to-mesenchymal transition, and increased cell proliferation (Leu et al., 2008) and metastasis (Benali et al., 2000) .
Importance of SST/sst system relates to its distinct ability to inhibit deregulated proliferation and invasion (Pola et al., 2003) . Thus, ssts activation triggers inhibitory cascades by mechanisms dependent and independent of Gi/o proteins (Moller et al., 2003) . This includes modulation of phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK/1/2) and Akt phosphorylation (Moller et al., 2003) , the two major signal transduction pathways involved in transformation, and enhanced proliferation and migration of cancer cells (Santen et al., 2002; Liu et al., 2007) . The antiproliferative effect of SST in breast cancer cells in vitro has long been known (Setyono-Han et al., 1987) , and the particular role of sst2 has been further dissected recently by showing that it mediates an antiproliferative action in MCF-7 cells by inducing apoptosis and G1/S cell cycle arrest, and decreasing expression of epidermal growth factor receptor (He et al., 2009) . Similarly, SST inhibits proliferation and migration of other cancer cells through downregulation of Akt and/ or ERK cascades (Pola et al., 2003; Sun et al., 2007) . SST analogs result effective in vivo, inhibiting the growth of induced xenografts and animal tumors (Keri et al., 1996; Kahan et al., 1999) , as well as counteracting the growth of neuroendocrine tumors, where they act by downregulating the ERK cascade (Hubina et al., 2006) .
In striking contrast to the compelling experimental evidence gathered in favor of a potential clinical and therapeutic benefit for SST in breast cancer, and despite the successful application of SST analogs to treat pituitary adenomas and neuroendocrine tumors (Rinke et al., 2009; Ben-Shlomo and Melmed 2010) , the early, scarce clinical studies reporting treatment of breast cancer patients with SST analogs only demonstrated, at best, a limited success (Watt et al., 2008) . Here, we provide evidence that a new factor in the SST/ssts system, sst5TMD4, is present in breast cancer, where it may counteract normal inhibitory function of SST/sst2 signaling.
Results
sst5TMD4 expression associates with poor prognosis markers in breast cancers sst5TMD4 expression was screened in a closed random series of tumor breast samples classified as poorly differentiated grade 3 (G3) tumors and in four negative controls from normal mammary glands. sst5TMD4 mRNA was detected in 28% of 49 breast cancer samples and was undetectable in the rest of samples, including the negative controls (Supplementary Figure 1) . Comparison of sst5TMD4 expression with pathological classification of each tumor revealed that presence of sst5TMD4 was correlated with absence of immunoreactivity to p53 (P ¼ 0.037), Her2neu (P ¼ 0.038) and estrogen receptor (P ¼ 0.053; Figure 1 ). Additionally, sst5TMD4 expression was directly and strongly correlated with tumors that metastasize to lymph nodes (Pp0.001; Figure 1 ).
Sst2 was ubiquitously expressed in both normal and tumor samples (Supplementary Figure 1) . Interestingly, expression levels of sst2 and sst5TMD4 were positively correlated (R 2 ¼ 0.715, P ¼ 0.013) in tumors expressing both the receptors (Figure 2a ).
Physical and functional interaction between sst5TMD4 and sst2
Confocal microscopy studies revealed that sst5TMD4 presence modifies subcellular sst2 localization. Indeed, sst2 expressed alone in CHO-K1 cells predominantly resides at the plasma membrane, whereas sst5TMD4 distribution is preferentially intracellular. However, when sst2 and sst5TMD4 receptors are expressed in the same cell, both colocalize, mainly at intracellular compartments ( Figure 2b ). Similar results were obtained using immunohistochemistry for endogenous sst2 and sst5TMD4 receptors in MCF-7 cells (Figure 2c ). Moreover, sst5TMD4 also modifies subcelullar sst5 localization when both receptors, transfected or endogenous, are coexpressed in CHO-K1 or MCF-7 cells, respectively (Figures 2f and g ).
Application of a fluorescence resonance energy transfer (FRET) technique revealed that sst2 constitutively forms homodimers/multimers, as indicated by a 67% FRET efficiency value, and that sst5TMD4 also homodimerizes (with lower efficiency, 43% FRET value; Supplementary Figure 2) . Furthermore, competitive FRET assays demonstrated that transfection with an equimolecular amount of untagged sst5TMD4 reduces sst2 FRET efficiency by 35%, whereas a sst5TMD4 fivefold higher quantity reduces this value by 63% (Figure 2d ), thus indicating the ability of sst5TMD4 to prevent sst2 homodimerization. Importantly, physical interaction of coexpressed sst5TMD4 and sst2 translated into functional interaction. Specifically, the capacity of sst2-transfected-CHO-K1 cells to increase free-cytosolic calcium ([Ca 2 þ ] i ), in response to SST is reduced when cells also expressed sst5TMD4 (Figure 2e ). In contrast, sst5TMD4 failed to alter sst5 homodimerization and did not influence its ability to respond to SST (Figures 2h and i) , supporting the selectivity of the truncated receptor to regulate, specifically, the functioning of sst2. ). Pictures show MCF-7 cells immunolabelled with sst2 or sst5 (green) and sst5TMD4 (red). Measurements of competitive FRET assays using CHO-K1 cells transfected with tagged-sst2 (d) or tagged-sst5 (h) and increasing amounts of untagged-sst5TMD4 (a, b and c indicate significant differences vs negative control, sst2 and sst2+sst5TMD4 1:1, respectively). Measurements of [Ca 2 þ ] i in CHO-K1 cells transiently transfected with sst2 alone or in combination with sst5TMD4 (e) and with sst5 alone or in combination with sst5TMD4 (i) in response to SST (a indicates significant differences vs sst2). In all cases, the data represent the mean ± s.e.m. and colocalization of each pair of receptors is shown in yellow.
Somatostatin receptor sst5TMD4 in breast cancer M Durán-Prado et al Characterization of MCF-7 ssts expression profile To explore the role and functionality of sst5TMD4 in a homologous model, we used the breast cancer cell line MCF-7, which expresses sst2, sst5 and sst5TMD4. Interestingly, the expression pattern of truncated sst5 was modified during culturing ( Figure 3a) . Specifically, sst5TMD4 mRNA completely disappeared after 10 passages (Figure 3b) , as confirmed by the absence of its protein (Figure 3c ). Conversely, full-length sst5 and sst2 mRNAs were not altered during culturing (Figure 3a) . This feature provided a suitable tool to investigate the role of endogenous sst5TMD4, as it enabled to study functioning of MCF-7 expressing or lacking sst5TMD4 ('initial passages' and 'final passages', respectively) without the need of silencing its expression, while reintroducing sst5TMD4 using an expression plasmid (or use of an empty vector; mock) served as controls for the study and ensured that the effects observed were unequivocally attributable to this receptor. sst5TMD4 influences epithelial/mesenchymal phenotype of MCF-7 cells More than 20% of sst5TMD4-transfected-MCF-7 cells exhibited a mesenchymal-like phenotype, in contrast to a lower 5% in mock-transfected-MCF-7 cells (Figure 3f ). Moreover, expression of the epithelial marker Ecadherin was decreased by 75% in cells expressing sst5TMD4 as compared with mock controls (P ¼ 0.005; Figure 3g ). Accordingly, E-cadherin protein levels were also significantly reduced in these cells (P ¼ 0.008; Figure 3g ). The percentage of cells exhibiting a mesenchymal-like phenotype was also increased in cells from initial passages that expressed the endogenous sst5TMD4 compared with cells from final passages that do not express the receptor (Supplementary Figure 3) . Furthermore, E-cadherin expression is 400% higher in cells from final passages than that of cells from initial passages (Supplementary Figure 3) . sst5TMD4 regulates MAPKs and Akt phosphorylation in MCF-7 cells MCF-7 cells of initial passages, which express sst5TMD4, exhibited higher levels of p-ERKs/ERKs (P ¼ 0.040) and p-Akt/Akt (P ¼ 0.002) than MCF-7 cells of final passages, which lack sst5TMD4 (Figures 4a and c). In line with this, sst5TMD4-stably-transfected-MCF-7 cells also displayed higher phosphorylation levels of both the kinases as compared with mock-transfected-MCF-7 cells (P ¼ 0.006 and P ¼ 0.003, respectively; Figures 4b and d) .
Measurement of [Ca
Time-course experiments also revealed differences between MCF-7 cells expressing or lacking sst5TMD4 in the regulation of these two kinase cascades in response to SST. Indeed, SST treatment comparably decreased basally elevated p-ERK1/2 levels in MCF-7 cells of initial passages and in sst5TMD4-stably-transfected cells, which thereby reached the low levels observed in MCF-7 cells of final passages (40% reduction, P ¼ 0.021) or in mock-transfected-MCF-7 cells (55% reduction, P ¼ 0.021), respectively. In contrast, SST treatment did not alter basal p-ERK levels in MCF-7 cells of final passages with or without stably-transfected empty vector (Figures 4a and b) . Of note, PI3K-Akt pathway was inversely regulated in MCF-7 cells by SST, which comparably increased p-Akt levels in cells expressing endogenous (42%, P ¼ 0.015) or transfected sst5TMD4 (48%, P ¼ 0.042), but did not alter p-Akt levels in sst5TMD4-lacking cells (Figures 4c and d ).
sst5TMD4 increases migration and invasion abilities of MCF-7 cells
Invasion assays showed that sst5TMD4-trasfected-MCF-7 cells, but not mock-transfected cells, were able to invade in response to a positive stimulus (Figure 5a ). Specifically, invasion of sst5TMD4-expressing MCF-7 cells was enhanced by 48% and 35% compared with control in matrigel-(P ¼ 0.032) and collagen-coated filters (P ¼ 0.029), respectively (Figure 5a ). Consistent with these findings, wound-healing assays showed higher ability to migrate in sst5TMD4-expressing MCF-7 cells than in mock-transfected cells (Po0.001; Figure 5b ). Treatment with SST did not modify the wound recovery 
% of cells vs. total
Somatostatin receptor sst5TMD4 in breast cancer M Durán-Prado et al ability of mock-transfected cells, whereas it completely restored the migratory ability of MCF-7 cells expressing sst5TMD4 to the levels observed in mock-transfected cells (Figure 5b ). The molecular basis of sst5TMD4-related functional changes was further explored by measuring expression levels of genes involved in cellular migration and invasion. Thus, presence of sst5TMD4 increased mRNA levels of three transcripts corresponding to the heptameric Arp2/3 complex as compared with mock-transfected cells (Arp2: 228%, P ¼ 0.007; Arp3: 223%, P ¼ 0.017; p16: 357%, P ¼ 0.044; Figure 5c ). Likewise, expression of the metalloprotease MMP-2, which was downregulated by 50% (P ¼ 0.011) in sst5TMD4-lacking cells (final passages; Figure 5d ), increased by threefold after reintroducing sst5TMD4 (P ¼ 0.035; Figure 5d ). A similar trend was observed for MMP-9 expression, though without reaching statistical significance (P ¼ 0.077 and P ¼ 0.180; Figure 5e ).
Presence of sst5TMD4 augments MCF-7 proliferation
The ability of sst5TMD4-expressing MCF-7 cells (initial passages) to proliferate was 30% higher (24 h; Po0.001) than that of sst5TMD4-lacking MCF-7 cells (final passages; Figure 6a ). Accordingly, MCF-7 cells stablytransfected with sst5TMD4 also showed a higher basal proliferation rate than mock-transfected cells (Po0.001; Figure 6a ). Furthermore, kinetic proliferation assays using stably-transfected-MCF-7 cells showed that cells transfected with sst5TMD4 proliferate more than mocktransfected cells, thus exhibiting a lower doubling time (P ¼ 0.037; Figure 6b) . Similarly, sst5TMD4-expressing cells displayed an increased exponential growing constant, K, compared with mock-transfected cells (P ¼ 0.041; Figure 6b ). Consistent with these results, mRNA levels of the positive cell cycle regulator cyclin D3 were increased by 175% (P ¼ 0.005) in sst5TMD4-transfected cells vs mock-transfected cells (Figure 6b ). Somatostatin receptor sst5TMD4 in breast cancer M Durán-Prado et al tumors induced with sst5TMD4-transfected-MCF-7 cells grew more than those induced with mock-transfected cells, this difference being significant after the fourth week of injection (76 vs 50 mm 3 , respectively; P ¼ 0.01; Figure 6c ) and maintained until the ninth week, when the experiment was ended (131 vs 102 mm 3 , respectively; P ¼ 0.03). Accordingly, the number of proliferating cells (positive for Ki-67) was 1.8-times higher in tumors induced with sst5TMD4-transfected-MCF-7 than in those induced with mock-transfected cells (P ¼ 0.0002; Figure 6d ). In addition, the expression of the metalloproteases MMP-2 and MMP-9 was increased in tumors induced with sst5TMD4-transfected cells, although the differences did not reach statistical significance ( Supplementary Figure 4 ; P ¼ 0.055 and P ¼ 0.07 for MMP-2 and MMP-9, respectively). Microscopic examination of HE-stained tumor xenografts showed that those induced with mock-transfected cells exhibited the typical histological morphology of a ductal breast tumor (Figure 6d ). On the other hand, those produced by sst5TMD4-transfected cells showed the morphology of an undifferentiated carcinoma (Figure 6d ), which correlated with a reduction in E-cadherin (Figure 6d ), a characteristic frequently found in more undifferentiated tumors. In fact, a 1.4-fold decrease in E-cadherin was detected in tumors induced with sst5TMD4-transfected cells as compared with tumors induced with mock-transfected cells (P ¼ 0.009; Figure 6d ).
Discussion
The (patho)physiological roles and potential therapeutic implications of the SST/ssts system present in breast cancer comprise a controversial, poorly known subject (Watt et al., 2008) . In line with previous studies showing that breast tumors express ssts, especially sst2 (Schulz et al., 1998; Orlando et al., 2004) , this latter receptor was frequently and abundantly expressed in the samples examined herein. In contrast, our results provide the first evidence that the newly identified truncated variant sst5TMD4, which is absent in normal mammary gland tissue, is present in human breast cancer, namely in roughly one third of the poorly differentiated grade 3 tumors analyzed. This is noteworthy because, as we reported recently, expression of sst5TMD4 is very uncommon, especially in normal tissues, where it is only found at low levels in lung, kidney, liver, brain, and is somewhat more abundant in several types of pituitary tumors (DuranPrado et al., 2009) . Interestingly, a reexamination of the literature unveiled two studies wherein the presence of sst5TMD4 could have been detected but left overlooked in breast tumors (Prevost et al., 1993; Xu et al., 1996) .
Additionally, sst5TMD4 seems to have a function of its own in MCF-7 cells, as its expression leads to a mesenchymal-like or fibroblastoid appearance, which contrasts with the usual epithelial morphology signature of this cell type. Moreover, sst5TMD4-transfected cells display increased migratory and proliferative abilities, and this may ultimately determine tumor progression and metastases. In this scenario, correlation between sst5TMD4 expression and bad prognosis markers in the breast tumors studied herein would suggest that presence of the truncated receptor may relate to this increased malignancy phenotype.
To investigate the molecular basis of sst5TMD4-induced changes in MCF-7 cells, we studied two major signal transduction pathways, Akt and ERK1/2, involved in proliferation, migration, and phenotype transformation in cancer cells (Santen et al., 2002; Liu et al., 2007) . Importantly, cells of initial passages, which endogenously express sst5TMD4, show higher level of p-Akt and p-ERK1/2 compared with cells of final passages, which lack sst5TMD4. Moreover, reintroduction of sst5TMD4 in MCF-7 cells of final passages increased both p-Akt and p-ERK1/2 levels to those observed in initial passages, which may in turn result in higher proliferation and migration rates. Indeed, phosphorylated Akt level is increased in 30-40% of breast cancers, where it promotes epithelial-to-mesenchymal transition and tumor progression to an invasive and metastatic carcinoma (Liu et al., 2007) . Consequently, Akt activation is associated to a decrease in disease-free survival and may have prognostic relevance in breast cancer (Perez-Tenorio and Stal 2002) . Several factors are known to activate the PI3K/Akt pathway including estrogens, IGF, EGF and HER2/neu. However, there is also evidence suggesting that additional, unknown factors operate in breast cancer to stimulate Akt network. Specifically, despite lacking ERs, progesterone receptors and HER2/neu, triple-negative breast cancers are also characterized by increased phosphorylation of Akt (Umemura et al., 2007) . Of note, we found an inverse correlation between sst5TMD4 expression and presence of both ERs and HER2/neu. To our knowledge, though Akt regulation by ssts is not novel (Charland et al., 2001) , this work provides the first evidence for a direct link between expression of an sst, Akt and breast cancer, and further, that the sole presence of a specific sst leads to increased p-Akt levels in a breast Somatostatin receptor sst5TMD4 in breast cancer M Durán-Prado et al cancer cell line. Obviously, more studies are warranted to determine whether sst5TMD4 can also increase basal levels of p-Akt in human primary breast tumors. Increased p-ERK1/2 levels induced by sst5TMD4 expression in MCF-7 cells may also be important. ERK1 and ERK2 are the most relevant MAP-kinases in breast cancer and are usually overexpressed and overphosphorylated in certain type of mammary tumors, especially, node-positive primary tumors (Santen et al., 2002) . Constitutive ERK signaling activation could derive to antiestrogen resistance (Donovan et al., 2001) , and increased p-ERK level is associated to poor survival in triple-negative cancers and is considered a poor prognosis factor (Eralp et al., 2008) . Some studies have linked ssts to ERK signaling (Pola et al., 2003) , where SST exerts a dual stimulatory/inhibitory effect on p-ERK and also on cell proliferation. Interestingly, SST inhibits p-ERK and cell proliferation (Pola et al., 2003) . When bearing in mind the ability of sst5TMD4 to act as dominant negative to sst2 signaling, it seems plausible that increased p-ERK levels could be related to a blockade of a constitutive inhibitory activity of sst2.
Analysis of ligand-induced signaling in cells expressing or lacking sst5TMD4 provided additional information on the complexity of the SST/sst system in cancer cells. Thus, treatment of sst5TMD4-expressing MCF-7 cells with SST divergently regulated Akt and ERK1/2 signaling pathways, where Akt phosphorylation increased whereas that of ERKs decreased. A similar, opposite regulation of PI3K-Akt and Raf/MEK/ERK1/2 pathways has been reported previously (Rommel et al., 1999) , although there is also evidence for positive cross-talk between these cascades (Vivanco and Sawyers 2002) . Primary evidence showing inhibition of ERK pathway by sustained high levels of Akt was reported in MCF-7 cells, where this cross-talk might switch the biological response to some compounds from growth arrest to proliferation (Zimmermann and Moelling 1999) . In this context, it seems plausible that the SST-induced increase in Akt phosphorylation observed in sst5TMD4-expressing MCF-7 cells leads to a concomitant inhibition of Raf-MEK-ERK1/2 pathway. This latter decrease may in turn underlie the SST-induced reduction in invasiveness observed in sst5TMD4-MCF-7 cells, as recent reports show that Raf-MEK-ERK1/2 signaling pathway is directly involved in cell invasion (Sawai et al., 2005) . Hence, when viewed together, our results support the notion that presence of sst5TMD4 can mediate disparate, ligand-dependent andindependent actions, which may result in separate control of distinct cellular functions, thereby providing a highly complex and versatile regulatory system that clearly deserves further investigation.
In addition, the sole presence of sst5TMD4 in MCF-7 cells increased expression of Arp2/3, a heptameric complex that activates actin filament nucleation and branching, and is essential in the enhanced ability of cancer cells to invade (Wang et al., 2005) . Arp2/3 proteins are upregulated in invasive and metastatic breast cancer cells (Wang et al., 2005) , and ablating its function blocks carcinoma cell invasiveness (Yamaguchi et al., 2005) . The sustained increase in basal p-ERK1/2 levels in sst5TMD4-expressing MCF-7 cells likely results in activation of the Arp2/3 complex (Nakanishi et al., 2007) , which can be enhanced by increased p-Akt (Lee et al., 2006) , and ultimately foster enhanced MCF-7 cell migration.
In sum, our results describe the presence of a new factor, sst5TMD4, in the scene of SST/ssts and breast cancer. Specifically, we show for the first time the presence of sst5TMD4 in sporadic ductal invasive breast cancer samples with bad prognosis and in MCF-7 cells, and demonstrate how this receptor alters the epithelial phenotype of these cells, increasing their basal ERK1/2 and Akt phosphorylation levels, and enhancing their capacity to grow and invade. The ability of sst5TMD4 to interact physically and functionally with sst2, disrupting a SST/sst2-mediated negative autocrine loop, provide the potential mechanism mediating its pathological function, and suggests novel avenues for research in the field of breast cancer.
Materials and methods

Breast samples
A series of 49 sporadic ductal breast carcinomas classified as high-grade tumors (G3) used in an earlier study (MorenoBueno et al., 2011) and four normal breast samples obtained from CNIO Tumor Bank (Madrid, Spain) were analyzed. The study was approved by the corresponding Ethics Committee. Mean patient age at surgery was 53 years (range, 27-87 years). Histological and immunohistochemical analysis classified the 49 samples as positive or negative carcinomas for estrogen receptor, p53, Her2neu and invasiveness, which was assessed by using metastases to lymph nodes as criterion.
Cell lines MCF-7 and CHO-K1 cells (ATCC, Manassas, VA, USA) were maintained in Dulbecco's Modified Eagle Medium and F12 medium, respectively, supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic and 2 mM L-glutamine, and maintained at 37 1C and 5% CO 2 .
Plasmids and transfection
Construction of fluorescent-protein-tagged sst2, sst5 and sst5TMD4 plasmids has been previously reported (DuranPrado et al., 2009) . Cell lines were transfected using Lipofectamine-2000 (Gibco, Barcelona, Spain). Stable transfectants were selected with geneticin (Gibco) and characterized by immunolabeling and PCR. Stable MCF-7 cells transfected with empty pCDNA3.1 þ (mock) served as negative control.
Antisera
The specific rabbit-antiserum against sst5TMD4 has been previously described and characterized (Duran-Prado et al., 2009 ). Goat-anti-SST2 and goat-anti-SST5 were purchased from Santa Cruz (Santa Cruz, CA, USA). Mouse monoclonal anti-human Ki-67 was purchased from BD-Biosciences (Franklin Lakes, NJ, USA). Secondary antibodies were Alexa-Fluor-594-chicken anti-rabbit, Alexa-Fluor-488-donkey anti-goat, Alexa-Fluor-488-donkey anti-rat, Alexa-Fluor-594-chicken anti-mouse (Invitrogen, Barcelona, Spain). Antibody against total ERKs was from Santa Cruz and antibodies against phospho-ERKs (Phospho-p44/42-MAPK), Akt and phospho-Akt from Cell Signaling (Danvers, MA, USA). Secondary antibodies were horseradish-peroxidase-goat anti-rabbit and anti-mouse IgGs (Sigma, Barcelona, Spain). Rat anti-Ecadherin antibody and horseradish-peroxidase-goat anti-ratIgG were kindly provided by A Cano.
PCR and quantitative real-time PCR All PCRs were run with 100 ng of complimentary DNA. PCR was used to detect the presence of ssts in MCF-7 cells. Quantitative real-time PCR (qRT-PCR) was used to quantify sst2, sst5, sst5TMD4, Arp2, Arp3, p16, cyclin D3, E-cadherin, MMP-2, MMP-9 and 18S (internal standard; see primer sequences in Table 1 ). For PCR, we used EcoTaq polymerase (Ecogen, Barcelona, Spain). For qRT-PCR, we used a 2 Â IQ-SYBR-green mastermix (BioRad, Madrid, Spain). All PCR reactions were carried out in an iCycler IQ thermal cycler (BioRad).
Confocal imaging
CHO-K1 cells were cotransfected with sst2-YFP and sst5TMD4-CFP or sst5-CFP and sst5TMD4-YFP. After transfection (24 h), cells were fixed in 4% paraformaldehyde, and mounted. Images were acquired with a Leica-spectral-TCS-SP2-AOBS confocal-scanning-microscope (Leica Corp, Wetzlar, Germany). Analysis and merges were performed with ImageJ (NIH, Bethesda, MD, USA).
FRET measurements
Interaction between sst5TMD4 and sst2 or sst5 was evaluated by competitive FRET, wherein homodimerization of sst2 or sst5 is evaluated in the face of increasing amounts of untagged sst5TMD4. Images of transfected CHO-K1 cells were acquired with an inverted Nikon Eclipse TE2000E-microscope equipped with a 400-DCLP dichroic-filter (Chroma, Olching, Germany) and recorded with an ORCA-II-BT digital camera (Hamamatsu, Bridgewater, NJ, USA), both controlled with MetaMorph software (Molecular Devices, Woburn, MA, USA). Net FRET was calculated as reported in detail elsewhere (Duran-Prado et al., 2007) . Western blotting Presence of sst5TMD4 and phosphorylation level of ERK1/2 and Akt were assessed by standard western blotting procedures using antibodies described previously. For further details, see Supplementary Material and Methods.
In vitro proliferation, migration and invasion assays The ability of stably-transfected cells to proliferate, migrate and invade was evaluated by Alamar Blue reagent, wound-healing technique and a modified Boyden's chamber method, respectively. For further details, see Supplementary Material and Methods.
Xenografts
Animal maintenance and experiments were carried out following the European Regulations for Animal Care under the approval of the University of Cordoba Research Ethics Committee. Six-week-old female athymic Swiss nu/nu mice (Charles River Laboratories, Barcelona, Spain) were subcutaneously grafted in the flank with 2 Â 10 6 mock or sst5TMD4-stably-transfected-MCF-7 cells. Tumor growth was monitored weekly during 3 months by using a digital caliper and calculating tumor volume. Each tumor was dissected, fixed and sectioned for histopathological examination after hematoxylineosin staining. Some slides were immunostained for Ki-67 and E-cadherin as previously described (Sarrio et al., 2008) . Specifically, immunostaining was performed by the LSAB (Dako, Barcelona, Spain) method with a heat-induced antigen retrieval step. Once developed, cell nuclei were counterstained with eosin.
Statistics
Data are expressed as mean±s.e.m. obtained from, at least, three separate, independent experiments carried out on different days and with different cell preparations. Statistical analysis was carried out with SPSS 15 (IBM, Madrid, Spain), using Student's t-test followed by a Mann-Whitney statistical test or one-way ANOVA (Kruskal-Wallis test) followed by a statistical test for multiple comparisons (Dunn's test). Differences were considered significant at Pp0.05.
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